中西医结合治疗结核性胸膜炎的临床疗效分析

发布时间：2018-10-05 21:34

【摘要】：目的分析纤溶酶治疗结核性胸膜炎的临床疗效。方法按照随机抽取的方式将结核性胸膜炎患者110例分为研究组与对照组。所有患者均加强营养,合理调整饮食,给予常规抗结核药物治疗。研究组再次家畜上加用纤溶酶治疗。治疗一个月后,比较两组胸腔积液消失时间,胸膜粘连发生率,治疗总有效率,胸膜厚度变化。结果研究组、对照组胸腔积液消失时间分别为(13.9±1.7)天、(19.0±2.1)天,组间差异有统计学意义(P0.05);两组胸膜粘连发生率分别为3.6%(2/55)、16.4%(9/55),组间差异有统计学意义(P0.05);纤溶酶治疗结核性胸膜炎的总有效率(92.7%)明显高于常规治疗(81.8%),且组间差异有统计学意义(P0.05);研究组2周末、4周末胸膜厚度与对照组比较差异有统计学意义(P0.05)。结论在常规治疗基础上加用纤溶酶治疗结核性胸膜炎,可降低胸膜粘连、胸膜肥厚发生率,促进胸腔积液的消失,临床疗效明显,值得临床推广研究。
[Abstract]:Objective to analyze the clinical effect of plasminase on tuberculous pleurisy. Methods 110 patients with tuberculous pleurisy were randomly divided into study group and control group. All patients were fortified with nutrition, diet adjusted and treated with routine anti-tuberculosis drugs. The study group added fibrinolytic enzyme to domestic animals again. After one month of treatment, the time of pleural effusion disappearance, the incidence of pleural adhesion, the total effective rate and the change of pleural thickness were compared between the two groups. Results in the study group, the time of effusion disappeared in the control group was (13.9 卤1.7) days and (19.0 卤2.1) days, respectively. The incidence of pleural adhesion in the two groups was 3.6% (2 / 55) or 16.4% (9 / 55), respectively (P0.05), and the total effective rate of plasminase in the treatment of tuberculous pleurisy (92.7%) was significantly higher than that in the routine treatment (81.8%), and there was statistical difference between the two groups. The pleural thickness in the study group was significantly different from that in the control group at the end of 2 weeks and 4 weeks (P0.05). Conclusion the treatment of tuberculous pleurisy with fibrinolytic enzyme on the basis of routine treatment can reduce the incidence of pleural adhesion, pleural hypertrophy and promote the disappearance of pleural effusion.
【作者单位】： 平山县第二医院;
【分类号】：R521.7
，

本文编号：2254946